By Denny Jacob

Disc Medicine's MWTX-003, a treatment for patients with polycythemia vera, was granted fast track designation by the U.S. Food and Drug Administration.

Chief Executive John Quisel said the clinical-stage biopharmaceutical company plans to initiate a Phase 1 trial in the coming months.

MWTX-003 is an investigational monoclonal antibody designed to increase hepcidin production and suppress serum iron.

Polycythemia vera is a chronic and rare myeloproliferative neoplasm characterized by the abnormal proliferation of red blood cells.

Write to Denny Jacob at denny.jacob@wsj.com

(END) Dow Jones Newswires

September 20, 2023 17:03 ET (21:03 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.
Disc Medicine (NASDAQ:IRON)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Disc Medicine Charts.
Disc Medicine (NASDAQ:IRON)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Disc Medicine Charts.